|
시장보고서
상품코드
2038140
세계 사이클린 의존성 키나아제 9(CDK9) 시장 규모 : 억제제 유형별, 용도별, 최종 사용자별, 지역별 및 예측별Global Cyclin Dependent Kinase 9 Market Size By Type of Inhibitor, By Application, By End-Users (Pharmaceutical Companies, Research Institutions, Hospitals and Clinics, Contract Research Organizations ) By Geographic Scope And Forecast |
||||||
세계 사이클린 의존성 키나아제 9(CDK9) 시장 분석
Verified Market Research에 따르면, 세계 사이클린 의존성 키나아제 9(CDK9) 시장은 2025년에 1억 5,000만 달러로 평가되었고, 2033년까지 4억 달러에 달할 것으로 예상되며, 2027-2033년 연평균 12.0%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
사이클린 의존성 키나아제 9(CDK9) 시장은 유전자 전사 및 세포주기 진행을 조절하는 데 있어 매우 중요한 역할을 하기 때문에 세계 제약 및 생명공학 산업에서 점점 더 많은 관심을 받고 있습니다. CDK9는 RNA 중합효소 II의 활성을 조절하고 세포의 생존과 증식에 관여하는 유전자의 전사를 가능하게 하는 양성 전사신장 인자 복합체(P-TEFb)의 주요 구성요소입니다. CDK9 활성의 이상은 다양한 암 및 염증성 질환과 밀접한 관련이 있으며, 신약 개발 및 표적 치료의 매력적인 치료 표적이 되고 있습니다.
세계 사이클린 의존성 키나아제 9(CDK9) 시장 정의
사이클린 의존성 키나아제 9(CDK9) 시장은 유전자 전사와 세포주기 진행을 조절하는 중요한 효소인 CDK9를 표적으로 하는 치료제, 신약 후보물질 및 연구 솔루션 세계 시장입니다. CDK9는 RNA 중합효소 II를 통한 전사를 조절하는 양성 전사신장 인자 복합체(P-TEFb)의 일부를 구성합니다. CDK9의 비정상적인 활성은 암, 바이러스 감염, 염증성 질환 등의 질병에서 조절되지 않는 세포 증식 및 전사인자 이상과 밀접한 관련이 있어 현대 신약개발에서 중요한 표적이 되고 있습니다. 이 시장에는 주로 저분자 CDK9 억제제, 임상 개발 단계에 있는 임상시험용 약물, 제약 및 생명공학 연구에 사용되는 보조 연구 도구가 포함됩니다.
사이클린 의존성 키나아제 9(CDK9) 시장은 표적 암 치료에 대한 연구 확대, 항암제 개발에 대한 투자 증가, 전사 조절 요법에 대한 관심 증가에 힘입어 성장하고 있습니다. 제약 및 생명공학 기업, 학계 및 위탁 연구 기관들은 혈액암, 고형암 및 특정 바이러스성 질환을 치료하기 위해 CDK9 억제 전략을 적극적으로 모색하고 있습니다. 이 시장에는 전임상 및 임상 단계의 파이프라인 후보물질, 병용요법 연구, 치료의 정확성을 높이기 위한 바이오마커 개발도 포함됩니다. 분자생물학, 유전체학 및 정밀의료의 발전으로 신약개발이 가속화되고 있는 가운데, CDK9을 표적으로 하는 치료법은 차세대 종양학 및 전사조절 기반 치료법에서 점점 더 중요한 역할을 할 것으로 예측됩니다.
세계 사이클린 의존성 키나아제 9(CDK9) 시장 개요
사이클린 의존성 키나아제 9(CDK9) 시장은 암 치료에서 분자 및 전사 조절에 대한 관심이 높아짐에 따라 표적 항암제 분야에서 중요한 분야로 부상하고 있습니다. CDK9은 유전자 전사와 세포주기 진행을 조절하는 중요한 효소이며, 그 비정상적인 활성은 백혈병, 유방암, 폐암 등 다양한 암과 관련이 있는 것으로 알려져 있습니다. 이에 따라 제약사 및 생명공학 기업들은 발암성 전사인자 경로를 표적으로 삼아 종양의 성장을 억제하는 CDK9 억제제 개발에 많은 투자를 하고 있습니다. 세계 CDK9 시장은 표적치료제와 정밀의료 접근법의 발전에 힘입어 꾸준히 성장하고 있으며, 향후 10년간 강력한 성장이 예상됩니다.
세계적으로 증가하는 암 부담은 CDK9을 표적으로 하는 치료제에 대한 수요를 촉진하는 주요 요인 중 하나입니다. CDK9 억제제는 초기 단계의 임상시험에서 특히 혈액암과 고형암에서 유망한 결과를 보여주어 추가 연구 개발을 촉진하고 있습니다. 또한, 암 연구에 대한 투자 증가, 제약회사와 연구기관과의 협력 확대, 그리고 신약개발 기술의 발전이 신규 CDK9 억제제 개발을 가속화하고 있습니다. 이러한 혁신은 약물의 선택성, 효능 및 안전성 프로파일을 향상시켜 CDK9 기반 치료제의 치료 잠재력을 확대하는 데 기여하고 있습니다.
지역별로 보면, 북미는 강력한 생명공학 생태계, 높은 연구개발비, 풍부한 임상시험 인프라로 인해 현재 CDK9 시장을 독점하고 있습니다. 한편, 아시아태평양은 헬스케어 투자 증가, 암 발병률 증가, 정부의 제약 연구 지원 노력으로 인해 예측 기간 동안 가장 빠른 성장을 보일 것으로 예측됩니다. 주요 제약사 및 생명공학 기업들이 파트너십, 임상시험 및 종양학 분야의 미충족 수요를 충족시키기 위한 신약 개발 프로그램을 통해 파이프라인을 확장함에 따라 시장 경쟁이 치열해지고 있습니다.
Global Cyclin Dependent Kinase 9 Market Analysis
According to Verified Market Research, the Global Cyclin Dependent Kinase 9 Market was valued at USD 150 Million in 2025 and is estimated to reach USD 400 Million by 2033, growing at a CAGR of 12.0% from 2027 to 2033.
The Cyclin-Dependent Kinase 9 (CDK9) market is gaining increasing attention in the global pharmaceutical and biotechnology industries due to its crucial role in regulating gene transcription and cell cycle progression. CDK9 is a key component of the positive transcription elongation factor complex (P-TEFb), which controls RNA polymerase II activity and enables the transcription of genes involved in cell survival and proliferation. Dysregulation of CDK9 activity has been strongly associated with various cancers and inflammatory disorders, making it an attractive therapeutic target for drug discovery and targeted therapies.
Global Cyclin Dependent Kinase 9 Market Definition
The Cyclin-Dependent Kinase 9 Market refers to the global market for therapeutics, drug candidates, and research solutions targeting CDK9, a critical enzyme involved in regulating gene transcription and cell cycle progression. CDK9 forms part of the positive transcription elongation factor complex (P-TEFb), which controls RNA polymerase II-mediated transcription. Because abnormal CDK9 activity is strongly associated with uncontrolled cell proliferation and transcriptional dysregulation in diseases such as cancer, viral infections, and inflammatory disorders, it has become an important target in modern drug discovery. The market primarily includes small-molecule CDK9 inhibitors, investigational drugs in clinical development, and supporting research tools used in pharmaceutical and biotechnology research.
The Cyclin Dependent Kinase 9 Market is driven by growing research in targeted cancer therapies, increasing investment in oncology drug development, and rising interest in transcription-regulating therapeutic approaches. Pharmaceutical and biotechnology companies, academic institutions, and contract research organizations are actively exploring CDK9 inhibition strategies for treating hematologic malignancies, solid tumors, and certain viral diseases. The market also includes preclinical and clinical pipeline candidates, combination therapy research, and biomarker development aimed at improving treatment precision. As advances in molecular biology, genomics, and precision medicine continue to accelerate drug discovery, CDK9-targeted therapies are expected to play an expanding role in next-generation oncology and transcription-based therapeutics.
Global Cyclin Dependent Kinase 9 Market Overview
The Cyclin Dependent Kinase 9 (CDK9) Market is emerging as a significant segment within the targeted oncology therapeutics landscape, driven by the increasing focus on molecular and transcriptional regulation in cancer treatment. CDK9 is a key enzyme involved in regulating gene transcription and cell cycle progression, and its abnormal activity has been linked to various cancers, including leukemia, breast cancer, and lung cancer. As a result, pharmaceutical and biotechnology companies are investing heavily in the development of CDK9 inhibitors to target oncogenic transcription pathways and suppress tumor growth. The global CDK9 market has been experiencing steady expansion and is projected to grow strongly over the next decade, supported by advancements in targeted therapy and precision medicine approaches.
The rising global burden of cancer remains one of the primary factors fueling the demand for CDK9-targeted therapeutics. CDK9 inhibitors have demonstrated promising results in early-stage clinical trials, particularly in hematologic malignancies and solid tumors, encouraging further research and clinical development. In addition, increasing investments in oncology research, growing collaborations between pharmaceutical companies and research institutions, and technological advancements in drug discovery are accelerating the development of novel CDK9 inhibitors. These innovations are improving drug selectivity, efficacy, and safety profiles, thereby expanding the therapeutic potential of CDK9-based treatments.
Regionally, North America currently dominates the CDK9 market due to its strong biotechnology ecosystem, high R&D spending, and robust clinical trial infrastructure. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth during the forecast period owing to rising healthcare investments, increasing cancer incidence, and supportive government initiatives for pharmaceutical research. Market competition is intensifying as key pharmaceutical and biotechnology companies expand their pipelines through partnerships, clinical trials, and new drug development programs aimed at addressing unmet medical needs in oncology.
Global Cyclin Dependent Kinase 9 Market: Segmentation Analysis
The Global Cyclin Dependent Kinase 9 Market is segmented based on Type of Inhibitor, Application, End-Users, and Geography.
Global Cyclin Dependent Kinase 9 Market by Type of Inhibitor
Selective CDK9 Inhibitors
Non-Selective CDK Inhibitors
Combination Inhibitors
Based on Type of Inhibitor, Selective CDK9 inhibitors are projected to grow the fastest due to their higher target specificity, improved efficacy, and lower off-target toxicity compared with non-selective CDK inhibitors. Advances in drug design and growing clinical evidence supporting their effectiveness in targeting transcription-driven cancers are accelerating their development and adoption in oncology therapies.
Global Cyclin Dependent Kinase 9 Market by Application
Cancer Treatment
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Other Applications
Based on Application, Cancer treatment dominates growth due to the strong role of CDK9 in regulating transcription of oncogenes and anti-apoptotic proteins (such as MYC and MCL-1) that drive tumor proliferation and survival. Inhibiting CDK9 suppresses cancer cell growth and induces apoptosis, making CDK9 inhibitors a promising therapeutic strategy currently being widely explored in preclinical and clinical oncology research.
Global Cyclin Dependent Kinase 9 Market by End-Users
Pharmaceutical Companies
Research Institutions
Hospitals and Clinics
Contract Research Organizations (CROs)
Based on End-Users, The Contract Research Organizations (CROs) segment is expected to be the fastest-growing end-user segment in the Cyclin Dependent Kinase 9 (CDK9) Market. The growth is driven by the increasing outsourcing of drug discovery, preclinical studies, and clinical trials by pharmaceutical companies to CROs in order to reduce development costs and accelerate timelines for targeted therapies such as CDK9 inhibitors.
Global Cyclin Dependent Kinase 9 Market by Geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Based on Geography, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Asia Pacific is expected to witness the highest growth due to the rising prevalence of cancer, increasing healthcare expenditure, and expanding pharmaceutical R&D activities in countries such as China, Japan, and India. Additionally, improving healthcare infrastructure and growing adoption of advanced targeted therapies are accelerating the demand for CDK9 inhibitors in the region.
Global Cyclin Dependent Kinase 9 Market Competitive Landscape
The Global Cyclin Dependent Kinase 9 Market is highly fragmented with the presence of a large number of players. Some of the major companies include Astex Pharmaceuticals Inc AstraZeneca Plc, Bayer AG, Cyclacel Pharmaceuticals Inc Eli Lilly and Company, Jayant Technologies Inc Selvita SA, Tolero Pharmaceuticals Inc Tragara Pharmaceuticals Inc Vichem Chemie Research Ltd, ViroStatics srl, among others.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 MARKET DEFINITION
- 1.2 MARKET SEGMENTATION
- 1.3 RESEARCH TIMELINES
- 1.4 ASSUMPTIONS
- 1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
- 2.1 DATA MINING
- 2.2 SECONDARY RESEARCH
- 2.3 PRIMARY RESEARCH
- 2.4 SUBJECT MATTER EXPERT ADVICE
- 2.5 QUALITY CHECK
- 2.6 FINAL REVIEW
- 2.7 DATA TRIANGULATION
- 2.8 BOTTOM-UP APPROACH
- 2.9 TOP-DOWN APPROACH
- 2.10 RESEARCH FLOW
- 2.11 DATA END USER
3 EXECUTIVE SUMMARY
- 3.1 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETOVERVIEW
- 3.2 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETESTIMATES AND FORECAST (USD BILLION)
- 3.3 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETECOLOGY MAPPING
- 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
- 3.5 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETABSOLUTE MARKET OPPORTUNITY
- 3.6 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETATTRACTIVENESS ANALYSIS, BY REGION
- 3.7 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETATTRACTIVENESS ANALYSIS, BY TYPE OF INHIBITOR
- 3.8 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETATTRACTIVENESS ANALYSIS, BY APPLICATION
- 3.9 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETATTRACTIVENESS ANALYSIS, BY END USER
- 3.10 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETGEOGRAPHICAL ANALYSIS (CAGR %)
- 3.11 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET, BY TYPE OF INHIBITOR (USD BILLION)
- 3.12 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET, BY APPLICATION (USD BILLION)
- 3.13 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET, BY END USER (USD BILLION)
- 3.14 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET, BY GEOGRAPHY (USD BILLION)
- 3.15 FUTURE MARKET OPPORTUNITIES
4 MARKET OUTLOOK
- 4.1 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETEVOLUTION
- 4.2 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKETOUTLOOK
- 4.3 MARKET DRIVERS
- 4.4 MARKET RESTRAINTS
- 4.5 MARKET TRENDS
- 4.6 MARKET OPPORTUNITY
- 4.7 PORTER'S FIVE FORCES ANALYSIS
- 4.7.1 THREAT OF NEW ENTRANTS
- 4.7.2 BARGAINING POWER OF SUPPLIERS
- 4.7.3 BARGAINING POWER OF BUYERS
- 4.7.4 THREAT OF SUBSTITUTE TYPE OF INHIBITORS
- 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
- 4.8 VALUE CHAIN ANALYSIS
- 4.9 PRICING ANALYSIS
- 4.10 MACROECONOMIC ANALYSIS
5 MARKET, BY TYPE OF INHIBITOR
- 5.1 OVERVIEW
- 5.2 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TYPE OF INHIBITOR
- 5.3 SELECTIVE CDK9 INHIBITORS
- 5.4 NON-SELECTIVE CDK INHIBITORS
- 5.5 COMBINATION INHIBITORS
6 MARKET, BY APPLICATION
- 6.1 OVERVIEW
- 6.2 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
- 6.3 CANCER TREATMENT
- 6.4 CARDIOVASCULAR DISEASES
- 6.5 NEUROLOGICAL DISORDERS
- 6.6 INFECTIOUS DISEASES
- 6.7 OTHER APPLICATIONS
7 MARKET, BY END USER
- 7.1 OVERVIEW
- 7.2 GLOBAL CYCLIN DEPENDENT KINASE 9 MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USER
- 7.3 PHARMACEUTICAL COMPANIES
- 7.4 RESEARCH INSTITUTIONS
- 7.5 HOSPITALS AND CLINICS
- 7.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
8 MARKET, BY GEOGRAPHY
- 8.1 OVERVIEW
- 8.2 NORTH AMERICA
- 8.2.1 U.S.
- 8.2.2 CANADA
- 8.2.3 MEXICO
- 8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 U.K.
- 8.3.3 FRANCE
- 8.3.4 ITALY
- 8.3.5 SPAIN
- 8.3.6 REST OF EUROPE
- 8.4 ASIA PACIFIC
- 8.4.1 CHINA
- 8.4.2 JAPAN
- 8.4.3 INDIA
- 8.4.4 REST OF ASIA PACIFIC
- 8.5 LATIN AMERICA
- 8.5.1 BRAZIL
- 8.5.2 ARGENTINA
- 8.5.3 REST OF LATIN AMERICA
- 8.6 MIDDLE EAST AND AFRICA
- 8.6.1 UAE
- 8.6.2 SAUDI ARABIA
- 8.6.3 SOUTH AFRICA
- 8.6.4 REST OF MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
- 9.1 OVERVIEW
- 9.2 KEY DEVELOPMENT STRATEGIES
- 9.3 COMPANY REGIONAL FOOTPRINT
- 9.4 ACE MATRIX
- 9.4.1 ACTIVE
- 9.42 CUTTING EDGE
- 9.4.3 EMERGING
- 9.4.4 INNOVATORS
10 COMPANY PROFILES
- 10.1 OVERVIEW
- 10.2 ASTEX PHARMACEUTICALS INC
- 10.3 ASTRAZENECA PLC
- 10.4 BAYER AG
- 10.5 CYCLACEL PHARMACEUTICALS INC
- 10.6 ELI LILLY AND COMPANY
- 10.7 JAYANT TECHNOLOGIES INC
- 10.8 SELVITA SA
- 10.9 TOLERO PHARMACEUTICALS INC
- 10.10 TRAGARA PHARMACEUTICALS INC
- 10.11 VICHEM CHEMIE RESEARCH LTD
